PT - JOURNAL ARTICLE AU - S. Fu AU - J. J. Kavanagh AU - W. Hu AU - R. C. Bast TI - Clinical application of oxaliplatin in epithelial ovarian cancer AID - 10.1136/ijgc-00009577-200609000-00001 DP - 2006 Sep 01 TA - International Journal of Gynecologic Cancer PG - 1717--1732 VI - 16 IP - 5 4099 - http://ijgc.bmj.com/content/16/5/1717.short 4100 - http://ijgc.bmj.com/content/16/5/1717.full SO - Int J Gynecol Cancer2006 Sep 01; 16 AB - Platinum remains the most active drug class in ovarian cancer treatment; however, new single-agent and combination therapies are needed to improve the clinical outcome of ovarian cancer therapies. Oxaliplatin, a third-generation platinum derivative, has shown effective antitumor activity and a favorable toxicity profile in epithelial ovarian cancer. Preclinical evidence of the synergistic cytotoxic effect of oxaliplatin in combination with several other chemotherapeutic agents and clinical evidence of the absence of any dose-limiting hematologic toxicity associated with this agent have made oxaliplatin an attractive compound for combination agent therapy. This article reviews the current status of the clinical application of oxaliplatin alone and in a combination regimen in epithelial ovarian cancer treatment.